Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator.
Tissue plasminogen activator (tPA) is able to dissolve any fibrin material that forms in the anterior chamber or vitreous humor. This property has been reported by various experimental studies performed in rabbits. The authors demonstrate the tPA eye drops administered to patients with postoperative hyphema, which did not respond to traditional therapy, gave rapid clearance of the clot. Following its topical administration for the first time in patients, the harmless nature of the drug is emphasized as well as its efficacy. This study indicates the promising features of this drug which deserve further investigation.
Cellini
M
M
Università degli Studi di Bologna, Istituto di Clinica Oculistica, Italy.
Baldi
A
A
Possati
G L
GL
D000287:Administration, Topical; D000368:Aged; D005260:Female; D005337:Fibrin; D006801:Humans; D006988:Hyphema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D009883:Ophthalmic Solutions; D012163:Retinal Detachment / Q000601:surgery; D012591:Scleral Buckling; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D014821:Vitrectomy / Q000009:adverse effects*
D009883:Ophthalmic Solutions; D005337:Fibrin; D010959:Tissue Plasminogen Activator